Hand-Dermatitis Incidence in 298 Nurses Versus 101 Office Employees
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, activity or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at new hospital employment, wet work and early symptom onset. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 371 nurses and 111 office employees newly employed at a university hospital; incidence analysis excluded prior symptoms, leaving 298 nurses and 101 office employees |
| Design | Retrospective cohort using validated symptom questions |
| Timepoint | Employment beginning in 1987–1988 through September 1989 |
| Key result | Estimated incidence was 6.5 cases per 1,000 person-months in nurses and 1 per 1,000 person-months in office employees; 72% of nurse cases occurred within three months. |
How to interpret the result
The early concentration of cases supports prevention at job entry, while the retrospective assumptions make the incidence approximate rather than exact.
Important limitation: Only half of cases recalled an exact onset month, incidence required assumptions for missing dates, and the historical workplace may not reflect current hygiene practices.
Questionnaires, examinations, patch tests, chemical analyses and trial models answer different questions. A positive screening result, symptom report or association can guide a next step, but it does not diagnose the cause of one person’s rash. Clinician-directed testing is interpreted alongside timing, distribution and verified exposures.
Questions to ask next
- What exactly was measured: reported symptoms, visible signs, allergy, work loss, performance or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the design compare groups or follow change over time, and what factors could still explain the difference?
- Would occupational-health review, clinician examination or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 8314610
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.